Chemotherapie beim Hund – wann ist sie sinnvoll?

D. Krastel

doi:10.1055/s-0038-1623028

Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere, Table of Contents

Tierarztl Prax Ausg G Grosstiere Nutztiere 2010; 38(S 01): S33-S36
DOI: 10.1055/s-0038-1623028

Ausgewählter Kongressbeitrag

Schattauer GmbH

Chemotherapie beim Hund – wann ist sie sinnvoll?

Studienergebnisse zur Behandlung des malignen Lymphoms und Mastzelltumors

D. Krastel

¹Klinik für Kleintiere (Direktor: Prof. Dr. G. Oechtering), Veterinärmedizinische Fakultät der Universität Leipzig

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Abbo AH, Lucroy MD. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993–2006). J Am Vet Med Assoc 2007; 231: 1836-1842.
2 Cooper M, Tsai X, Bennett P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet Comp Oncol 2009; 7: 196-206.
3 Fournel-Fleury C, Magnol JP, Bricaire P, Marchal T, Chabanne L, Delverdier A. et al. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol 1997; 117: 35-59.
4 Frimberger AE, Moore AS, Rassnick KM, Cotter SM, O'Sullivan JL, Quesenberry PJ. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006; 20: 355-364.
5 Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A. et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008; 22: 1301-1309.
6 Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Lara-Garcia A, Kosarek CE. et al. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. J Vet Intern Med 2007; 21: 1355-1363.
7 Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S. et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008; 22: 985-988.
8 London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP. et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009; 15: 3856-3865.
9 MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?. J Vet Intern Med 2005; 19: 732-736.
10 Maglennon GA, Murphy S, Adams V, Miller J, Smith K, Blunden A. et al. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours. Vet Comp Oncol 2008; 6: 268-274.
11 Marconato L, Bonfanti U, Stefanello D, Lorenzo MR, Romanelli G, Comazzi S. et al. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference?. Vet Comp Oncol 2008; 6: 80-89.
12 Miller AG, Morley PS, Rao S, Avery AC, Lana SE, Olver CS. Anemia is associated with decreased survival time in dogs with lymphoma. J Vet Intern Med 2009; 23: 116-122.
13 Murphy S, Sparkes AH, Smith KC, Blunden AS, Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec 2004; 154: 743-746.
14 Northrup NC, Harmon BG, Gieger TL, Brown CA, Carmichael KP, Garcia A. et al. Variation among pathologists in histologic grading of canine cutaneous mast cell tumors. J Vet Diagn Invest 2005; 17: 245-248.
15 Northrup NC, Howerth EW, Harmon BG, Brown CA, Carmicheal KP, Garcia AP. et al. Variation among pathologists in the histologic grading of canine cutaneous mast cell tumors with uniform use of a single grading reference. J Vet Diagn Invest 2005; 17: 561-564.
16 Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984; 21: 469-474.
17 Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K. et al. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 2004; 167: 158-166.
18 Rassnick KM, Moore AS, Collister KE, Northrup NC, Kristal O, Chretin JD. et al. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. J Vet Intern Med 2009; 23: 317-322.
19 Risbon RE, de Lorimier LP, Skorupski K, Burgess KE, Bergman PJ, Carreras J. et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999–2004). J Vet Intern Med 2006; 20: 1389-1397.
20 Scase TJ, Edwards D, Miller J, Henley W, Smith K, Blunden A. et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006; 20: 151-158.
21 Vaughan A, Johnson JL, Williams LE. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med 2007; 21: 1332-1339.
22 Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res 2008; 4: 32.
23 Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, Hansen K. et al. CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med 2006; 20: 136-143.
24 Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002; 39: 529-535.